AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29020372 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolcapone 200 mg
Number of subjects: 27
Study 25050456 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin DPI 32.5 mg
Number of subjects: 16
Study 25050456 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin DPI 65 mg
Number of subjects: 16
Study 25050456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 23772186 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer buddy system (PBS) to promote CPAP adherence
Number of subjects: 52
Study 23772186 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 52
Study 21718908 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome present (+MetS)
Number of subjects: 2248
Study 21718908 — intervention group
Group type: EXPERIMENTAL
Intervention: Low high-density lipoprotein cholesterol
Number of subjects: 2248
Study 21718908 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 2248
Study 21718908 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated glucose
Number of subjects: 2248
Study 21718908 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (unadjusted)
Number of subjects: 2248
Study 21718908 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (adjusted)
Number of subjects: 2248
Study 21718908 — intervention group
Group type: COMPARATOR
Intervention: Early percutaneous coronary intervention
Number of subjects: 2248
Study 19549287 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic intravenous alanyl‐glutamine dipeptide (20 g for 5 days)
Number of subjects: 44
Study 19549287 — intervention group
Group type: COMPARATOR
Intervention: Control group (same chemotherapy regimens as screening cycle)
Number of subjects: 44
Study 17560446 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (3-h intervals)
Number of subjects: 2066
Study 17560446 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (3-h intervals)
Number of subjects: 2066
Study 17560446 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (12-h intervals)
Number of subjects: 2066
Study 17560446 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (12-h intervals)
Number of subjects: 2066
Study 15140778 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised tools (ST)
Number of subjects: 2957
Study 15140778 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercises (EX)
Number of subjects: 2957
Study 15140778 — intervention group
Group type: EXPERIMENTAL
Intervention: Both tools and exercises (ST+EX)
Number of subjects: 2957
Study 15140778 — intervention group
Group type: COMPARATOR
Intervention: Usual care (C)
Number of subjects: 2957
Study 11426001 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mmol/L gadoteridol
Number of subjects: 156
Study 11426001 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mmol/L gadoteridol
Number of subjects: 156
Study 11426001 — intervention group
Group type: COMPARATOR
Intervention: Ringer solution
Number of subjects: 156
Study 10025043 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific acupuncture therapy (verum)
Number of subjects: 24
Study 10025043 — intervention group
Group type: COMPARATOR
Intervention: Non-specific acupuncture therapy (placebo)
Number of subjects: 24
Study 8008413 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine (30 mg) administered intravenously
Number of subjects: 0
Study 8008413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1987713 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (80 mg/day, 4 times per day)
Number of subjects: 10
Study 1987713 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (80 mg/day)
Number of subjects: 10
Study 1987713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 735882 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 10
Study 31060604 — intervention group
Group type: EXPERIMENTAL
Intervention: INCREM (Functional Remediation + Computerized Cognitive Training)
Number of subjects: 81
Study 31060604 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation plus online games
Number of subjects: 81
Study 31060604 — intervention group
Group type: COMPARATOR
Intervention: Treatment As Usual (TAU)
Number of subjects: 81
Study 27884418 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 cGy dose of radiation
Number of subjects: 147
Study 27884418 — intervention group
Group type: COMPARATOR
Intervention: 700 cGy dose of radiation
Number of subjects: 147
Study 25881841 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Disc Arthroplasty (TDA)
Number of subjects: 4
Study 25881841 — intervention group
Group type: COMPARATOR
Intervention: Anterior Cervical Discectomy and Fusion (ACDF)
Number of subjects: 4
Study 23204536 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief smoking cessation intervention
Number of subjects: 2
Study 16759297 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 717
Study 16759297 — intervention group
Group type: COMPARATOR
Intervention: Past smokers
Number of subjects: 717
Study 16759297 — intervention group
Group type: COMPARATOR
Intervention: Never smokers
Number of subjects: 717
Study 14769785 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy
Number of subjects: 180
Study 14769785 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfafurazole (sulphisoxazole) 50 mg/kg body weight, given once a day for six months
Number of subjects: 180
Study 14769785 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 10935668 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic nurse and pharmacist led education including an interactive Kodak Photo‐CD Portfolio technique
Number of subjects: 130
Study 10935668 — intervention group
Group type: COMPARATOR
Intervention: Conventional information
Number of subjects: 130
Study 10935668 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic education
Number of subjects: 130
Study 8873199 — intervention group
Group type: EXPERIMENTAL
Intervention: High involvement (student loan) with high intonation and intensity of voice
Number of subjects: 279
Study 8873199 — intervention group
Group type: EXPERIMENTAL
Intervention: Low involvement (ATM cards) with low intonation and intensity of voice
Number of subjects: 279
Study 8873199 — intervention group
Group type: EXPERIMENTAL
Intervention: High involvement (student loan) with low intonation and intensity of voice
Number of subjects: 279
Study 8873199 — intervention group
Group type: EXPERIMENTAL
Intervention: Low involvement (ATM cards) with high intonation and intensity of voice
Number of subjects: 279
Study 8873199 — intervention group
Group type: EXPERIMENTAL
Intervention: Characteristics of voice (intensity and intonation)
Number of subjects: 279
Study 1738544 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticarcillin disodium and clavulanate potassium (Timentin) administered intravenously at the time of surgery and for 12 hours postoperatively, followed by oral amoxicillin and clavulanate potassium (Augmentin) therapy for an additional seven days
Number of subjects: 101
Study 1738544 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered intravenously at the time of surgery and for 12 hours postoperatively, followed by placebo for an additional seven days
Number of subjects: 101
Study 6391067 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine (up to 12 mg a day for 6 weeks)
Number of subjects: 10
Study 6391067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31339676 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Number of subjects: 613
Study 31339676 — intervention group
Group type: COMPARATOR
Intervention: Low-dose efavirenz (EFV400)
Number of subjects: 613
Study 26919705 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentation with chin bone
Number of subjects: 93
Study 26919705 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentation with chin bone plus a membrane
Number of subjects: 93
Study 26919705 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentation with a bone substitute plus a membrane
Number of subjects: 93
Study 25444377 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents
Number of subjects: 1498
Study 25444377 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents
Number of subjects: 1498
Study 23534416 — intervention group
Group type: COMPARATOR
Intervention: Established Market Economies
Number of subjects: 11140
Study 23534416 — intervention group
Group type: EXPERIMENTAL
Intervention: Eastern Europe
Number of subjects: 11140
Study 23534416 — intervention group
Group type: EXPERIMENTAL
Intervention: Asia
Number of subjects: 11140
Study 21854383 — intervention group
Group type: EXPERIMENTAL
Intervention: Forensic statement analysis (FSA) methods
Number of subjects: 35
Study 21854383 — intervention group
Group type: COMPARATOR
Intervention: Deceptive eyewitness accounts
Number of subjects: 35
Study 19423519 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizers with SPF 15
Number of subjects: 30
Study 19423519 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizers with no stated SPF
Number of subjects: 30
Study 19423519 — intervention group
Group type: COMPARATOR
Intervention: Sunscreen with SPF 30 or 45
Number of subjects: 30
Study 16236787 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated trials
Number of subjects: 0
Study 16236787 — intervention group
Group type: COMPARATOR
Intervention: Nonrepeated trials
Number of subjects: 0
Study 16236787 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus presentation durations longer than required for recognition (2 s)
Number of subjects: 0
Study 16236787 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus presentation durations close to the minimum time required for recognition (85-101 ms)
Number of subjects: 0
Study 12942722 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (CA) monotherapy - 300 mg/day
Number of subjects: 70
Study 12942722 — intervention group
Group type: COMPARATOR
Intervention: Maximal androgenic block (MAB) - CA + surgical castration - 200 mg/day
Number of subjects: 70
Study 12942722 — intervention group
Group type: COMPARATOR
Intervention: Maximal androgenic block (MAB) - CA + drug castration - 200 mg/day
Number of subjects: 70
Study 10575270 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose BCG regimen
Number of subjects: 0
Study 10575270 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-rate BCG regimen
Number of subjects: 0
Study 10575270 — intervention group
Group type: COMPARATOR
Intervention: BCG immunotherapy (standard regimen)
Number of subjects: 0
Study 9161270 — intervention group
Group type: EXPERIMENTAL
Intervention: Samarium compound filter with E-speed film
Number of subjects: 39
Study 9161270 — intervention group
Group type: COMPARATOR
Intervention: Conventional aluminum filter with E-speed film
Number of subjects: 39
Study 1533209 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 20
Study 1533209 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 20
Study 3880867 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin C (10 g daily)
Number of subjects: 100
Study 3880867 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 3880867 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin C
Number of subjects: 100
Study 31243803 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron isomaltoside 1000 (IIM)
Number of subjects: 1512
Study 31243803 — intervention group
Group type: COMPARATOR
Intervention: Iron sucrose (IS)
Number of subjects: 1512
Study 30033196 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT) applied every 3 days for children with up to three incontinence episodes per day, and daily for those with more frequent episodes
Number of subjects: 62
Study 30033196 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 62
Study 26629967 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-hydroxyphthalic anhydride-modified bovine beta-lactoglobulin (JB01)
Number of subjects: 38
Study 25260813 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful radial access (RA)
Number of subjects: 241
Study 25260813 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful femoral access (FA)
Number of subjects: 241
Study 25260813 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover (failed RA with need for bailout FA)
Number of subjects: 241
Study 22803423 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI + DG group (Rabeprazole 20 mg once daily; DG 6 g thrice daily)
Number of subjects: 186
Study 22803423 — intervention group
Group type: COMPARATOR
Intervention: Control group A (Rabeprazole Capsule 20 mg once daily)
Number of subjects: 186
Study 22803423 — intervention group
Group type: COMPARATOR
Intervention: Control group B (Rabeprazole 20 mg once daily; Domperidone 10 mg thrice daily)
Number of subjects: 186
Study 22803423 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 186
Study 20139291 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended model of care (usual care + self-management group intervention)
Number of subjects: 77
Study 20139291 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 77
Study 16831828 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclooxygenase-2 and TNFα inhibitors
Number of subjects: 70
Study 16831828 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient years
Number of subjects: 70
Study 16831828 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual standard incidence ratios (SEER)
Number of subjects: 70
Study 16047527 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemarketing
Number of subjects: 0
Study 16047527 — intervention group
Group type: EXPERIMENTAL
Intervention: Academic detailing (personal visits)
Number of subjects: 0
Study 16047527 — intervention group
Group type: COMPARATOR
Intervention: Direct mail
Number of subjects: 0
Study 16047527 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained GPs
Number of subjects: 0
Study 16047527 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported GPs
Number of subjects: 0
Study 16047527 — intervention group
Group type: COMPARATOR
Intervention: Control GPs (written guidance only)
Number of subjects: 0
Study 14612286 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary trypsinogen activation peptide (TAP) at admission
Number of subjects: 41
Study 14612286 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary TAP concentrations on days 2 to 3
Number of subjects: 41
Study 14612286 — intervention group
Group type: EXPERIMENTAL
Intervention: APACHE II scores at 48 h after admission
Number of subjects: 41
Study 14612286 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission urinary TAP >=35 nmol/L for severe pancreatitis
Number of subjects: 41
Study 14612286 — intervention group
Group type: EXPERIMENTAL
Intervention: APACHE II scores (>=9) at 48 h after admission
Number of subjects: 41
Study 10395878 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-T vaccine
Number of subjects: 0
Study 10395878 — intervention group
Group type: COMPARATOR
Intervention: PRP vaccine
Number of subjects: 0
Study 10395878 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP-Hib combination vaccines
Number of subjects: 0
Study 7726672 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 58
Study 7726672 — intervention group
Group type: COMPARATOR
Intervention: Conventional cholecystectomy (CC)
Number of subjects: 58
Study 1903732 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH-a initiated during the luteal phase (Group B)
Number of subjects: 192
Study 1903732 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH-a initiated during the follicular phase (Group C)
Number of subjects: 192
Study 1903732 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group A) - pure FSH human menopausal gonadotropin (hMG) protocol
Number of subjects: 192
Study 1903732 — intervention group
Group type: EXPERIMENTAL
Intervention: Both GnRH-a protocols (Group B and C)
Number of subjects: 192
Study 1903732 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH-a during follicular phase (Group C)
Number of subjects: 192
Study 1903732 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH-a during luteal phase (Group B)
Number of subjects: 192
Study 1903732 — intervention group
Group type: EXPERIMENTAL
Intervention: All three protocols (A, B, C)
Number of subjects: 192
Study 6787107 — intervention group
Group type: EXPERIMENTAL
Intervention: Alrestatin
Number of subjects: 10
Study 6787107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31600487 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab monotherapy
Number of subjects: 1240
Study 31600487 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab combination therapy
Number of subjects: 1240
Study 31600487 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 1240
Study 31600487 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 1240
Study 31600487 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF therapy alone
Number of subjects: 1240
Study 31600487 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF therapy in combination with an immunomodulator
Number of subjects: 1240
Study 30209855 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity inspiratory muscle training (H-IMT) for 8 weeks, using threshold loading with a target workload of maximal inspiratory pressure (MIP) of at least 70%
Number of subjects: 45
Study 30209855 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity inspiratory muscle training at 10% of initial MIP
Number of subjects: 45
Study 30209855 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity inspiratory muscle training (H-IMT)
Number of subjects: 45
Study 30209855 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity inspiratory muscle training
Number of subjects: 45
Study 28504542 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 134
Study 28504542 — intervention group
Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 134
Study 25990414 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose combined oral contraceptive (ethinylestradiol 20 μg/desogestrel 150 μg)
Number of subjects: 67
Study 25990414 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-users of COCs)
Number of subjects: 67
Study 25990414 — intervention group
Group type: COMPARATOR
Intervention: Comparison of BMC percentage variation
Number of subjects: 67
Study 24078799 — intervention group
Group type: EXPERIMENTAL
Intervention: ACES-based curriculum
Number of subjects: 335
Study 24078799 — intervention group
Group type: COMPARATOR
Intervention: Standard sex education curriculum (Control)
Number of subjects: 335
Study 21416421 — intervention group
Group type: EXPERIMENTAL
Intervention: Entertainment-education (E-E) program
Number of subjects: 437
Study 21416421 — intervention group
Group type: COMPARATOR
Intervention: Educational program
Number of subjects: 437
Study 21416421 — intervention group
Group type: COMPARATOR
Intervention: Entertainment program
Number of subjects: 437
Study 19661809 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate risk case (n = 25)
Number of subjects: 86
Study 19661809 — intervention group
Group type: COMPARATOR
Intervention: High-risk paternal case (n = 33)
Number of subjects: 86
Study 19661809 — intervention group
Group type: COMPARATOR
Intervention: High-risk maternal case (n = 28)
Number of subjects: 86
Study 17907591 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-based budesonide inhaler therapy
Number of subjects: 321
Study 17907591 — intervention group
Group type: COMPARATOR
Intervention: CFC-based budesonide inhaler therapy
Number of subjects: 321
Study 17907591 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dosage (1,600 microg/day) HFA and CFC inhalers
Number of subjects: 321
Study 15534056 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F‐FDG imaging
Number of subjects: 59
Study 15534056 — intervention group
Group type: COMPARATOR
Intervention: Labeled leukocyte/marrow imaging
Number of subjects: 59
Study 11526761 — intervention group
Group type: EXPERIMENTAL
Intervention: Dienogest
Number of subjects: 34
Study 11526761 — intervention group
Group type: COMPARATOR
Intervention: Leuprolein acetate
Number of subjects: 34
Study 9146848 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam + Diltiazem (0.25 mg triazolam after 3-day treatment of 180 mg diltiazem)
Number of subjects: 7
Study 9146848 — intervention group
Group type: COMPARATOR
Intervention: Triazolam alone
Number of subjects: 7
Study 9146848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 7966506 — intervention group
Group type: EXPERIMENTAL
Intervention: Addiction Severity Index (ASI)
Number of subjects: 0
Study 2885203 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrivastine 8 mg
Number of subjects: 12
Study 2885203 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine 50 mg with alcohol 32 ml
Number of subjects: 12
Study 2885203 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrivastine 8 mg with alcohol 32 ml
Number of subjects: 12
Study 2885203 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 60 mg and 120 mg with alcohol 32 ml
Number of subjects: 12
Study 2885203 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrivastine 4 mg with alcohol 32 ml
Number of subjects: 12
Study 2885203 — intervention group
Group type: COMPARATOR
Intervention: Alcohol alone
Number of subjects: 12
Study 2885203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30458805 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined inspiratory and expiratory muscle training in same cycle (CTSC)
Number of subjects: 92
Study 30458805 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined inspiratory and expiratory muscle training in different cycles (CTDC)
Number of subjects: 92
Study 30458805 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT)
Number of subjects: 92
Study 30458805 — intervention group
Group type: COMPARATOR
Intervention: Sham training
Number of subjects: 92
Study 30458805 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined inspiratory and expiratory muscle training (CTSC and CTDC)
Number of subjects: 92